← Back to Search

Checkpoint Inhibitor

AraG PET Imaging for Lung Cancer

Phase 2
Recruiting
Led By Deepak Behera, MD
Research Sponsored by CellSight Technologies, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
ECOG performance status of 0, 1 or 2
Patients with a histologically confirmed NSCLC and planned to undergo immunotherapy as monotherapy or as combination therapy with concurrent as treatment for advanced/metastatic disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up two years
Awards & highlights

Summary

This trial is using AraG PET imaging to study the effectiveness of checkpoint inhibitor therapy for patients with NSCLC.

Who is the study for?
This trial is for adults with advanced non-small cell lung cancer (NSCLC) who are about to start immunotherapy. They should be relatively active and mobile (ECOG status 0-2), have a life expectancy of at least 6 months, and their disease must be measurable by certain medical criteria.
What is being tested?
The study tests how well [18F]F AraG PET imaging can show the body's immune response to checkpoint inhibitor therapy in NSCLC patients. It aims to measure changes in PET signals before and after treatment, linking these changes to the tumor's visible response on scans.
What are the potential side effects?
[18F]F AraG is a diagnostic agent used for imaging; side effects may include reactions at the injection site or allergic reactions. Checkpoint inhibitors can cause fatigue, skin reactions, inflammation of organs, flu-like symptoms, and other immune-related effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can take care of myself and perform daily activities.
Select...
I have NSCLC and am set to receive immunotherapy alone or with other treatments for advanced cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~two years
This trial's timeline: 3 weeks for screening, Varies for treatment, and two years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
[18F]F-AraG uptake signal

Find a Location

Who is running the clinical trial?

CellSight Technologies, Inc.Lead Sponsor
17 Previous Clinical Trials
234 Total Patients Enrolled
Deepak Behera, MDPrincipal InvestigatorCellSight Technologies, Inc.
~0 spots leftby Oct 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top